Teva/Barr Combination Creates Biosimilar Force
Teva’s $7.46 billion acquisition of Barr will result in a generics powerhouse, expanding U.S. leadership and geographic footprint.
Teva’s $7.46 billion acquisition of Barr will result in a generics powerhouse, expanding U.S. leadership and geographic footprint.